17 results about "Diagnostic Specificity" patented technology

The invention discloses application of a marker in preparation of a sicca syndrome diagnosis product, and a construction method and equipment of a diagnosis model, and relates to the technical field of sicca syndrome diagnosis. The sicca syndrome marker comprises a ratio of citrulline to arginine. The ratio of citrulline to arginine in serum has a close relationship with sicca syndrome, a diagnostic model developed based on the marker has the technical advantages of high diagnostic specificity, high sensitivity and good accuracy, and the detection method is simple, convenient and reliable and is easy to clinically popularize.

The invention discloses a colon cancer diagnostic marker screening method and system based on transcriptome data, and belongs to the technical field of biological information, and the method comprises the steps of data preparation, pathological hierarchical modeling, diagnostic marker screening and screening report generation. According to the method, pathological hierarchical modeling based on dynamic discrimination and double-layer feature fusion is adopted, on the basis of comprehensively considering gene expression and pathological morphology information, pathological subtypes of colon cancer samples are adaptively recognized, stable and representative subtype features are obtained, and therefore the accuracy and biological representativeness of diagnostic marker screening are improved; diagnostic marker screening based on pathological subtype difference analysis is adopted, and on the premise of considering pathological subtype characteristics, a stable and reliable diagnostic marker set with remarkable expression difference is screened in a targeted manner, so that the biological representativeness, screening robustness and diagnostic specificity of markers are improved.

The invention relates to the technical field of medical image processing and artificial intelligence auxiliary diagnosis, in particular to a medical image report generation informatization planning system, which comprises a multi-modal time sequence difference feature analysis module used for acquiring current medical image data and historical image data of a patient and generating a time sequence difference residual vector; the semantic entropy flow conservation and negentropy injection control module is used for calculating a system net entropy target; the dynamic planning generation module based on residual driving is used for generating a diagnosis report text sequence; the diagnostic specificity and normativity collaborative optimization module is used for constructing a composite loss function containing a cross entropy loss term and a specificity penalty term and carrying out iterative updating on system parameters based on the composite loss function, and the specificity penalty term is used for constraining the description accuracy of the generated text on the dynamic change of the image; the problem that the dynamic change of the disease course cannot be captured only by relying on static image analysis in the prior art is effectively solved.

The invention belongs to the technical field of biomedicine, and particularly relates to a method for detecting potential biomarkers of myocardial of an HFpEF mouse based on non-targeted metabonomics, which comprises the following steps: constructing an HFpEF mouse model by combining high fat diet with L-NAME, setting a conventional feeding control group, monitoring myocardial glucose metabolism through longitudinal [18F] FDG PET / CT, collecting myocardial tissues, and performing non-targeted metabonomics detection. And screening differential metabolites through Foldchange greater than or equal to 1.2 or less than or equal to 0.83 and p less than 0.05, and carrying out correlation analysis on the differential metabolites and [18F] FDG SUVmean to obtain 25 potential biomarkers. According to the method, the steps are clear and repeatable, the marker is directly related to myocardial energy metabolism, the diagnosis specificity is improved, and a support is provided for HFpEF targeted therapy research and development and molecular mechanism research.

The invention discloses a marker LGALS7 for diagnosing nasopharyngeal squamous cell carcinoma and application of the marker LGALS7, and belongs to the technical field of molecular diagnosis. Proteomics screening finds that LGALS7 is remarkably low in expression in nasopharyngeal squamous cell carcinoma tissues, which prompts that LGALS7 can be used as a biomarker for diagnosing nasopharyngeal squamous cell carcinoma. According to the invention, the diagnosis result obtained by detecting the LGALS7 by adopting an immunohistochemical method is higher in accuracy, and a support vector machine model is constructed based on the diagnosis result. A model evaluation result shows that the marker LGALS7 shows relatively high diagnosis specificity and sensitivity in a plurality of independent queues, squamous cell carcinoma from nasopharynx and squamous cell carcinoma from other parts can be effectively distinguished, and the problem of insufficient diagnosis specificity in the prior art is solved.

The invention relates to the field of diagnostic kits, in particular to application of an IGHV family molecule as a diagnostic marker in preparation of a diagnostic kit for psoriasis (PSO) and arthropathy type psoriasis (PsA), and the IGHV family molecule is selected from IGHV3-72, IGHV5-51, IGHG3, IGHV1-69, IGHV3-73 and / or IGHV3-9. Wherein the prediction efficiency of the IGHG3 is the highest, and the area under the curve (AUC) is 0.826 (95% CI: 0.693-0.959). IGHV family molecules are specifically expressed in psoriasis, the diagnosis specificity is high, and the cross reaction with other autoimmune diseases can be reduced; the invasive operation of skin biopsy can be avoided through nail sample detection; the kit is suitable for early screening of PSO, early diagnosis and prediction of PsA and dynamic monitoring of curative effect, and is widely applied.

The invention discloses a traditional Chinese medicine disease diagnosis auxiliary system based on a clinical mapping knowledge domain, and relates to the technical field of traditional Chinese medicine diagnosis. Searching syndrome nodes associated with the symptoms and tongue picture features from a traditional Chinese medicine clinical knowledge map to form an initial syndrome set; calculating a matching degree between the pulse condition waveform data and typical pulse condition features of each syndrome node, and performing sorting and screening to form a focused syndrome set; extracting associated treatment methods and prescriptions to generate a preliminary diagnosis reasoning chain; and performing logic verification and optimization on the reasoning chain through a graph neural network syndrome evolution deduction model, outputting an optimized diagnosis path, and recording related data to a diagnosis and treatment file. The system can assist in traditional Chinese medicine diagnosis, improve diagnosis pertinence and reasoning preciseness, and perfect diagnosis and treatment records.

The invention discloses a biomarker combination for Parkinson's disease diagnosis and a diagnosis and treatment application based on an LINC00467 / miR-494-3p / CYCS axis in the technical field of biological medicines. The invention provides a PD early diagnosis biomarker combination taking LINC00467, miR-494-3p and CYCS as cores, and a PD treatment scheme and a drug development direction taking the regulation axis as a target spot. The invention solves the technical problems of low specificity, dependence on clinical symptoms, scarcity of treatment targets and unclear mechanism of the existing PD diagnosis, and has important clinical application value and industrialization prospect.

This invention discloses a gene biomarker panel for detecting PCNSL based on cerebrospinal fluid (cerebrospinal fluid) ctDNA, relating to the fields of gene detection and molecular diagnostics. The gene biomarker panel includes MYD88, PIM1, CD79B, GNA13, IRF4, DTX1, KMT2D, and B2M. By detecting the mutation status of these genes in a subject's cerebrospinal fluid sample, the mutation status is input into a trained random forest classification model to generate auxiliary judgment results, providing molecular evidence for diagnosing PCNSL in the subject. This eight-gene combination panel has shown high diagnostic specificity in multiple cerebrospinal fluid ctDNA-based validation cohorts and has the ability to identify MYD88 wild-type PCNSL.

The application relates to the field of testing and analysis technology, and discloses a hyperspectral crop disease and pest early dynamic detection method and system, which comprises the following steps: constructing a circadian rhythm response vector baseline by collecting baseline hyperspectral images of crops in a key period; calculating the deviation degree of the circadian rhythm response vector of the day from the baseline in a monitoring period; and generating a warning signal when the deviation degree continuously abnormally changes. The application realizes the super-early identification of the initial stage of disease and pest infection by dynamically monitoring the physiological rhythm change of crops instead of static spectral characteristics. Meanwhile, the directionality characteristics of the asynchronous phase vector are used to analyze the stress type, and the diagnosis specificity is improved through micro-disturbance response verification, so that the traditional disease identification is changed from post-judgment to pre-warning, and reliable technical support is provided for precision agriculture.

The invention relates to the technical field of medical care informatics, and discloses a hysteroscope image auxiliary diagnosis and treatment evaluation system fusing traditional Chinese and western medicine multi-mode characterization, which comprises an optical field data acquisition module, a spectral texture orthogonal decoupling module, a heterogeneous flow field dynamic characterization module and a rheological state inversion mapping module, by decoupling specular reflection and diffuse reflection signals, a Qi-blood body fluid operation retardation quantitative index of a fluid drift model relative to an endometrial basement motion model is calculated, a light tissue relative slip vector is generated, a rheological characteristic index is inversed and is mapped to an orthogonal evaluation space in combination with chromaticity characteristics, and the evaluation accuracy is improved. According to the method, a microstate quantification mechanism based on fluid dynamics is constructed, the technical problem that the traditional Chinese medicine body fluid metabolism syndrome lacks objective physical characterization indexes is effectively solved, and the evaluation precision and diagnosis specificity of the pathological and physiological state of the uterine cavity microenvironment are improved.

The invention relates to application of platelet-derived protein in differential diagnosis of sepsis and sepsis shock. Specifically, the invention proposes that vesicle-related membrane protein 8 (VAMP8) in platelets and various differential proteins including VAMP2, SNAP23 and STX16 are used as key biomarkers for the first time to distinguish between sepsis patients and septic shock patients. Compared with the prior art, by detecting the expression levels of the specific proteins in the platelets, the severity of diseases can be distinguished more accurately and earlier on the molecular level, the diagnosis specificity is remarkably improved, and a new effective means is provided for clinical early warning and accurate intervention. The invention also provides a detection kit containing related reagents and a corresponding differential diagnosis method.

This invention belongs to the field of biotechnology and discloses a detectable and therapeutic antibody against the venom of the Chinese cobra and its uses. This invention provides an antibody or its antigen-binding fragment that can target and recognize different key toxin components or antigenic epitopes in venom, exhibiting excellent diagnostic specificity and therapeutic and preventative capabilities. Utilizing the high specificity of this antibody or its antigen-binding fragment in recognizing snake venom antigens, it can be developed into a rapid detection kit (such as a lateral flow immunochromatographic test strip) for rapid identification of the biting snake species and detection of the presence of specific snake venom in the environment or sample, providing crucial technical support for precise treatment and on-site diagnosis. It can also be used directly as a neutralizing agent for emergency treatment after snakebite. Through injection, the antibody can specifically neutralize the snake venom toxins entering the body, blocking its toxic effects and providing a novel and specific treatment method for clinical care.

The invention relates to the field of diagnostic kits, in particular to application of a complement component as a diagnostic marker in preparation of a psoriasis diagnostic kit, and the complement component is selected from C1R, C2, C1QC, C7, C6, C9, C4A and / or C1QB. The complement component is specifically expressed in psoriasis, the diagnosis specificity is high, and the cross reaction with other autoimmune diseases can be reduced; the invasive operation of skin biopsy can be avoided through nail sample detection; the kit is suitable for PSO early screening, PSA differential diagnosis and dynamic curative effect monitoring, and is wide in application.

This invention discloses the application of Sjögren's syndrome biomarkers in products for diagnosing Sjögren's syndrome and a method for constructing a diagnostic model for Sjögren's syndrome, relating to the field of Sjögren's syndrome diagnostic technology. The Sjögren's syndrome biomarker includes the Val to Phe ratio. The diagnostic model established based on this single biomarker has an AUC value greater than 0.9 on its ROC curve, exhibiting extremely high diagnostic specificity, sensitivity, and accuracy. Combinations of this biomarker with other biomarkers also demonstrate extremely high diagnostic efficacy. Therefore, the Sjögren's syndrome diagnostic biomarkers provided by this invention have promising application prospects in the diagnosis of Sjögren's syndrome.

The invention discloses a fusion protein antigen for diagnosing deer brucellosis, the amino acid sequence of the fusion protein antigen is SEQ ID No: 1, the amino acid sequences of dominant B cell antigen epitopes of brucella VirB1-VirB11 proteins are connected in series, a fusion protein gene is constructed, the proteins are expressed, and the fusion protein antigen is prepared. The fusion protein antigen for diagnosing deer brucellosis provided by the invention has high sensitivity and is suitable for early diagnosis; a specific cross experiment verifies that the fusion protein does not have cross reaction with positive serum of pathogenic bacteria of Escherichia coli, foot-and-mouth disease and fungal infection melanoderma, P / N values are all lower than 1.2, and the diagnosis specificity reaches 97.84%, so that the fusion protein provided by the invention does not have cross reaction with serum infected with other bacteria, thereby ensuring the detection accuracy.

This invention discloses a metabolomics-gut microbiome biomarker combination for the diagnosis of HIV-related asymptomatic neurocognitive impairment (ANI), comprising metabolomics biomarkers and gut microbiome biomarkers. The metabolomics biomarkers include plasma and fecal biomarkers. Plasma biomarkers include Asp-Asn and arachidonic acid, while fecal biomarkers include histidine, lysine, ornithine, and indolelactone. The gut microbiome biomarkers include phylum-level and genus-level biomarkers. Phylum-level biomarkers include Firmicutes, Actinobacteria, and Proteobacteria, while genus-level biomarkers include *Clostridium*, *Microbacterium*, *Klebsiella*, and *Prevotella*. This biomarker combination integrates the core differential features of metabolomics and gut microbiota, exhibiting high diagnostic specificity and sensitivity. It can effectively distinguish ANI patients from CI patients and healthy individuals, providing a clear target for HAND targeted intervention and possessing significant clinical application value.